In Silico and In Vitro Analyses Reveal Promising Antimicrobial Peptides from Myxobacteria
Open Access
- 31 December 2022
- journal article
- research article
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 15 (1) , 202-214
Abstract
Antimicrobial resistance (AMR) is a global concern, and as soon as new antibiotics are introduced, resistance to those agents emerges. Therefore, there is an increased appetite for alternative antimicrobial agents to traditional antibiotics. Here, we used in silico methods to investigate potential antimicrobial peptides (AMPs) from predatory myxobacteria. Six hundred seventy-two potential AMP sequences were extracted from eight complete myxobacterial genomes. Most putative AMPs were predicted to be active against Klebsiella pneumoniae with least activity being predicted against Staphylococcus aureus. One hundred seventeen AMPs (defined here as ‘potent putative AMPs’) were predicted to have very good activity against more than two bacterial pathogens, and these were characterized further in silico. All potent putative AMPs were predicted to have anti-inflammatory and antifungal properties, but none was predicted to be active against viruses. Twenty six (22%) of them were predicted to be hemolytic to human erythrocytes, five were predicted to have anticancer properties, and 56 (47%) were predicted to be biofilm active. In vitro assays using four synthesized AMPs showed high MIC values (e.g. So_ce_56_913 250 µg/ml and Coral_AMP411 125 µg/ml against E. coli). However, antibiofilm assays showed a substantial reduction in numbers (e.g. Coral_AMP411 and Myxo_mac104 showed a 69% and 73% reduction, respectively, at the lowest concentration against E. coli) compared to traditional antibiotics. Fourteen putative AMPs had high sequence similarity to proteins which were functionally associated with proteins of known function. The myxobacterial genomes also possessed a variety of biosynthetic gene clusters (BGCs) that can encode antimicrobial secondary metabolites, but their numbers did not correlate with those of the AMPs. We suggest that AMPs from myxobacteria are a promising source of novel antimicrobial agents with a plethora of biological properties.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- dPABBs: A Novel in silico Approach for Predicting and Designing Anti-biofilm PeptidesScientific Reports, 2016
- Bacterial predation: 75 years and counting!Environmental Microbiology, 2016
- Antimicrobial peptides and wound healing: biological and therapeutic considerationsExperimental Dermatology, 2016
- APD3: the antimicrobial peptide database as a tool for research and educationNucleic Acids Research, 2015
- Cationic Antimicrobial Peptides Cytotoxicity on Mammalian Cells: An Analysis Using Therapeutic Index Integrative ConceptInternational Journal of Peptide Research and Therapeutics, 2014
- BactPepDB: a database of predicted peptides from a exhaustive survey of complete prokaryote genomesDatabase: The Journal of Biological Databases and Curation, 2014
- In Silico Approach for Predicting Toxicity of Peptides and ProteinsPLOS ONE, 2013
- Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistanceJournal of Applied Microbiology, 2012
- Myxobacterial secondary metabolites: bioactivities and modes-of-actionNatural Product Reports, 2010
- DNA–DNA hybridization values and their relationship to whole-genome sequence similaritiesInternational Journal of Systematic and Evolutionary Microbiology, 2007